top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
MTU481
Multi tumor tissue array, 48 cases of 15 cancer types. Most types have duplicates or triplicates from different patients with grading and TNM staging data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$165
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
Human
48
48
1.5mm
4um
6
8
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in top 15 cancer types.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | M | 60 | Bladder, urinary | Transitional cell carcinoma | II | T4N0M0 | |
A02 | F | 30 | Breast | Invasive ductal carcinoma, tubular type | I~II | T3N0M0 | |
A03 | M | 45 | Lung | Small cell carcinoma | T2N1M0 | ||
A04 | M | 68 | Esophagus | Squamous cell carcinoma | II | T2N0M0 | |
A05 | F | 55 | Intestine, colon | Adenocarcinoma | II | T3N1M0 | |
A06 | M | 61 | Liver | Hepatocellular carcinoma | I~II | T2N0M0 | |
A07 | F | 58 | Ovary | Endometrioid adenocarcinoma | III | T2N0M0 | |
A08 | M | 75 | Prostate | Hyperplasia | |||
B01 | M | 61 | Bladder, urinary | Transitional cell carcinoma | II | T3N0M0 | |
B02 | F | 54 | Breast | Invasive lobular carcinoma | I | T3N1M0 | |
B03 | M | 58 | Lung | Squamous cell carcinoma | II~III | T2N0M0 | |
B04 | M | 66 | Esophagus | Squamous cell carcinoma | I~II | T3N0M0 | |
B05 | M | 67 | Intestine, colon | Adenocarcinoma | II | T3N1M0 | |
B06 | M | 29 | Liver | Hepatocellular carcinoma | II | T4N0M0 | |
B07 | F | 58 | Ovary | Serous cystadenocarcinoma | I~II | T2N0M0 | |
B08 | M | 69 | Prostate | Adenocarcinoma | III | T2N0M0 | |
C01 | M | 57 | Bladder, urinary | Transitional cell carcinoma | I~II | T2N0M0 | |
C02 | F | 43 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
C03 | M | 59 | Lung | Squamous cell carcinoma | II | T2N1M0 | |
C04 | M | 47 | Stomach | Adenocarcinoma | II | T3N2M0 | |
C05 | M | 76 | Intestine, colon | Adenocarcinoma | III | T3N1M0 | |
C06 | M | 55 | Liver | Hepatocellular carcinoma | III | T3N0M0 | |
C07 | F | 51 | Ovary | Adenocarcinoma | II | T2N0M0 | |
C08 | F | 55 | Skin | Normal | |||
D01 | F | 57 | Uterus, cervix | Squamous cell carcinoma | III | T1N1M0 | |
D02 | F | 39 | Breast | Invasive ductal carcinoma | I | T4N1M0 | |
D03 | F | 46 | Lung | Adenocarcinoma | II~III | T3N1M0 | |
D04 | M | 72 | Stomach | Adenocarcinoma | II~III | T3N2M0 | |
D05 | M | 73 | Intestine, rectum | Adenocarcinoma | II | T2N0M0 | |
D06 | M | 48 | Kidney | Clear cell carcinoma | T1N0M0 | ||
D07 | F | 43 | Uterus, endometrium | Adenocarcinoma | II | T1N0M0 | |
D08 | M | 58 | Skin | Squamous cell carcinoma | I~II | T1N0M0 | |
E01 | F | 31 | Uterus, cervix | Squamous cell carcinoma | II~III | T2N0M0 | |
E02 | F | 38 | Breast | Invasive ductal carcinoma | III | T2N1M0 | |
E03 | F | 50 | Lung | Adenocarcinoma | III | T2N1M0 | |
E04 | F | 54 | Stomach | Adenocarcinoma | II | T3N2M0 | |
E05 | M | 79 | Intestine, rectum | Adenocarcinoma | II | T2N0M0 | |
E06 | F | 64 | Kidney | Clear cell carcinoma | T1N0M0 | ||
E07 | F | 49 | Uterus, endometrium | Adenocarcinoma | I~II | T2N0M0 | |
E08 | M | 48 | Lymph node, inguinal | Metastatic melanoma | |||
F01 | F | 52 | Uterus, cervix | Squamous cell carcinoma | III | T1N0M0 | |
F02 | F | 75 | Breast | Invasive ductal carcinoma | III | T3N0M0 | |
F03 | M | 80 | Lung | Adenocarcinoma | II~III | T3N0M0 | |
F04 | M | 20 | Intestine, small intestine | Adenocarcinoma | I | T3N2M0 | |
F05 | F | 65 | Intestine, rectum | Adenocarcinoma | II | T2N0M0 | |
F06 | M | 54 | Kidney | Clear cell carcinoma | T2N0M0 | ||
F07 | F | 58 | Uterus, endometrium | Adenocarcinoma | III | T1N0M0 | |
F08 | M | 28 | Tonsil | Tonsillitis | |||
null |
bottom of page